KPV Dosage Guide for Researchers: Protocols and Reconstitution

Overview

KPV (Lysine-Proline-Valine) is a tripeptide used in experimental research for its anti-inflammatory properties, particularly in gut inflammation models. This guide provides a practical reference for researchers working with KPV in laboratory settings, covering reconstitution, dosing ranges observed in published studies, and storage protocols.

> Research Use Only: KPV is sold exclusively for in-vitro and preclinical laboratory research. It is not intended for human or animal therapeutic use.

Reconstitution Protocol

KPV is typically supplied as a lyophilized (freeze-dried) powder. Standard reconstitution uses bacteriostatic water (BW) or sterile saline:

1. Allow the vial to reach room temperature before opening
2. Inject bacteriostatic water slowly along the vial wall — do not inject directly onto the powder
3. Gently swirl (do not shake) until fully dissolved
4. The solution should be clear and colorless; discard if particulate matter is present

Typical reconstitution concentration: 1–5 mg/mL depending on study design

Dosing Ranges in Published Research

The following ranges reflect doses used in peer-reviewed preclinical studies. These are not clinical recommendations.

| Study Model | Route | Dose Range | Reference | |---|---|---|---| | DSS-induced colitis (mouse) | Oral / IP | 0.1–1 mg/kg/day | Kannengiesser et al., 2008 | | Skin wound healing (mouse) | Topical | 0.01–0.1% solution | Bohm et al., 2005 | | Intestinal epithelial cell culture | In vitro | 10–100 μM | Dalmasso et al., 2008 | | Nanoparticle-encapsulated (mouse) | Oral | 0.5 mg/kg | Laroui et al., 2014 |

Storage Conditions

- Lyophilized powder: Store at -20°C, protected from light; stable for 24+ months - Reconstituted solution: Store at 2–8°C; use within 28 days - Avoid repeated freeze-thaw cycles, which degrade peptide integrity - Use amber vials or foil wrapping to minimize UV exposure

Study Design Considerations

Researchers designing KPV studies should consider:

- Route of administration: Oral delivery is feasible due to PepT1-mediated transport, but bioavailability varies significantly between models. Intraperitoneal (IP) administration provides more consistent systemic exposure in rodent studies. - Nanoparticle encapsulation: Published literature suggests significantly enhanced colonic delivery with hydrogel nanoparticle formulations compared to free peptide — relevant for IBD model studies. - Endpoint selection: Common endpoints in KPV gut research include colon length, histological damage scoring (e.g., modified Dieleman score), myeloperoxidase (MPO) activity, and mucosal cytokine panels (TNF-α, IL-6, IL-1β, IL-10). - Combination protocols: KPV has been co-studied with other anti-inflammatory peptides and compounds; researchers should account for potential additive or synergistic effects in study design.

Purity & Quality Standards

For reproducible research outcomes, KPV should meet the following minimum standards: - Purity: ≥98% by HPLC - Identity confirmation: Mass spectrometry (MS) verification - Endotoxin testing: <1 EU/mg for in vivo studies - Certificate of Analysis (COA): Required from an accredited third-party laboratory

Pure Pharm Peptides provides independent third-party COA documentation for all research compounds.

---

This guide is intended for scientific reference only. All compounds are for research use only and not for human or animal consumption.

See Also: KPV Peptide Research Overview · Peptide Reconstitution Guide · Peptide Storage & Stability Guide